Serratus Anterior Block and Erector Spinae Block in Postoperative Analgesia

Postoperative Analgesia Clinical Trial

Official title:

Evaluation of the Effect of Serratus Anterior Block and Erector Spinae Block on Postoperative Analgesia in Thoracic Surgeries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04579302
• Other study ID #: AP2007-50105
• Status: Completed
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: February 28, 2021

Study information

• Verified date: March 2021
• Source: National Cancer Institute, Egypt
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

90 patients scheduled for thoracic cancer surgeries, allocated in 3 groups for serratus anterior block and erector spinae block and control group. during anaesthesia:total intraoperative fentanyl required will be recorded. After surgery, all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded.

Description:

90 patients scheduled for thoracic cancer surgeries, allocated in 3 groups for serratus anterior block (SAB) and erector spinae block (ESB) and control group. During anaesthesia: total intraoperative fentanyl required will be recorded. After surgery, all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded. Other secondary outcomes are: numerical rating scales and postoperative pulmonary functions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: February 28, 2021
• Est. primary completion date: February 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with class II physical status (American Society of Anaesthesiologists) ,
• Age between 18-70 years,
• Scheduled for thoracic cancer surgery

Exclusion Criteria:

• Patient refusal.
• Local infection at the site of the block.
• Cardiac dysfunction (ejection fraction <45%).
• Significant respiratory disorders.
• Preexisting neurological or psychiatric disease.
• Allergy to one of the study drugs.
• Pregnancy.
• Coagulopathy

Related Conditions & MeSH terms

• Postoperative Analgesia

Intervention

Procedure:
• Serratus anterior block (SAB)
Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
• Erector spinae block
Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%

Drug:
• Saline (as a placebo)
Patients will receive a sham block with 20 ml saline (as a placebo)
• Bupivacaine
bupivacaine

Locations

Country	Name	City	State
Egypt	National Cancer Institute	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	total morphine consumption in first postoperative 24 hours	the amount of morphine required to relieve pain will be recorded	first 24 postoperative hours
Secondary	intraoperative fentanyl requirement	the amount of fentanyl required during anaesthesia will be recorded	during anaesthesia
Secondary	numerical rating scale	numerical rating scale (from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain) will be recorded in different time intervals during the first 24 hours after surgery	the first 24 postoperative hours
Secondary	pulmonary functions	FVC and FEV1 will be recorded at 24 hours after surgery	24 hours after surgery